Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Experimental agent shrinks HIV reservoir, but fails to delay viral rebound.
Can photodynamic therapy eliminate the virus that causes cervical, anal and oral cancer?
The inability to precisely assess reservoir size has greatly hindered efforts to determine the effects of experimental cure therapies.
Researchers examined differences in the strength of a gene called nef.
Today, with better understanding of the complex task at hand, cure researchers are investigating multiple avenues and taking the long view.
An HIV immunotherapy method performs well in early safety trial.
Our January/February cover guys—David Massey and Johnny Lester (aka David & Johnny)—are a serodiscordant couple.
Beginning six months of treatment within two days following infection prevented viral rebound in at least some animals in a recent study.
Here are the HIV treatment news stories with the most views this year.
Researchers believe that macrophage cells in the liver that harbor such inert HIV are not a part of the viral reservoir.
As a result, cure treatments may have to approach these two targets differently.
The latest collection of articles stems from a tiny study in Uganda, neither peer-reviewed nor presented at a conference.
Post-HIV-treatment viral control is more likely in those treated very early.
A new study analyzes nuances in a cohort of six people who also received stem cell transplants for blood cancers.
An antibody treatment plus an immune-stimulating agent delayed viral rebound in primates infected with HIV-like virus.
Scientists have discovered a swifter and more precise way to edit the genome of immune cells, opening doors for cancer and HIV therapies.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.